Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
Molecular Weight:
206.28
Purity:
99.38
CAS Number:
[1002101-19-0]
Formula:
C13H18O2
Target:
Free Fatty Acid Receptor,GPR84
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted